Fox Run Management L.L.C. Purchases Shares of 25,422 ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Fox Run Management L.L.C. purchased a new position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 25,422 shares of the biopharmaceutical company’s stock, valued at approximately $466,000.

Other institutional investors have also recently modified their holdings of the company. R Squared Ltd bought a new stake in ACADIA Pharmaceuticals in the 4th quarter worth approximately $47,000. Quest Partners LLC lifted its holdings in shares of ACADIA Pharmaceuticals by 42.3% in the 3rd quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company’s stock worth $54,000 after acquiring an additional 1,047 shares during the last quarter. KBC Group NV boosted its stake in shares of ACADIA Pharmaceuticals by 67.0% in the 4th quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company’s stock valued at $93,000 after purchasing an additional 2,044 shares in the last quarter. Globeflex Capital L P bought a new position in shares of ACADIA Pharmaceuticals during the 4th quarter valued at $168,000. Finally, Xponance Inc. purchased a new position in ACADIA Pharmaceuticals in the 4th quarter worth $186,000. 96.71% of the stock is currently owned by institutional investors.

ACADIA Pharmaceuticals Stock Performance

Shares of NASDAQ:ACAD opened at $17.11 on Wednesday. The firm has a market capitalization of $2.85 billion, a P/E ratio of 21.94 and a beta of 0.43. The stock has a 50 day moving average price of $18.36 and a 200-day moving average price of $17.02. ACADIA Pharmaceuticals Inc. has a 52-week low of $14.15 and a 52-week high of $20.68.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ACAD. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $28.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Thursday, February 27th. Deutsche Bank Aktiengesellschaft started coverage on ACADIA Pharmaceuticals in a research report on Tuesday, February 11th. They set a “hold” rating and a $22.00 price target on the stock. StockNews.com upgraded ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, March 8th. Guggenheim cut shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their target price for the stock from $23.00 to $20.00 in a report on Friday, January 3rd. Finally, HC Wainwright reiterated a “buy” rating and set a $27.00 price target on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th. Eight investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $23.93.

Insiders Place Their Bets

In other ACADIA Pharmaceuticals news, Director Elizabeth A. Garofalo sold 4,919 shares of the company’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $18.23, for a total value of $89,673.37. Following the sale, the director now owns 17,595 shares in the company, valued at approximately $320,756.85. This represents a 21.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last 90 days, insiders sold 6,167 shares of company stock worth $114,583. 28.30% of the stock is owned by corporate insiders.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.